nasal continuous positive airway pressure less than or equal to 6 cm H2O
DeviceLow level continuous positive airway pressure delivered during sleep.
Other names: Cloud9™ nasal CPAP device and nasal interface
NCT Number: NCT01949584
This is a prospective, interventional, study in which patients with a history of habitual snoring to determine whether low pressure nasal continuous airway pressure can reduce the frequency, duration or intensity of snoring in subjects with mild to moderate snoring who do not have Obstructive Sleep Apnea (OSA).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
NeuroTrials Research, Inc., Atlanta, Georgia, United States
In this a prospective, interventional, study, each patient will be studied four times. Subjects without OSA will undergo an initial observational control study to establish the presence of snoring (session 1); a single CPAP titration night to determine the minimally effective CPAP level (session 2) to alleviate snoring; a subsequent full night of CPAP treatment at this CPAP level (CPAP not to exceed 6 cm H2O) using the Cloud9™ low-pressure CPAP device (session 3); and a final control night of study conducted off CPAP to assess whether the patient's snoring remained stable over time (session 4). In this study, each subject shall serve as his/her own control.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Inclusion criteria
for treatment trials (Nights 2 and 3):
Exclusion criteria
Low level continuous positive airway pressure delivered during sleep.
Other names: Cloud9™ nasal CPAP device and nasal interface
Time frame: single night of sleep
The primary objective of this study is to demonstrate that minimally effective nasal CPAP (≤ 6 cm H2O) delivered by the Cloud9™ device reduces the number of snoring events and reduces snoring intensity in habitual, simple snorers in treatment session 3. We will test the hypothesis that the Cloud9™ device will decrease the number of loud snores by 50% or decrease the overall number of snores by 50%.
Time frame: two different single nights
Safety- Adverse events associated with the Cloud9™ device (nasal or skin irritation, epistaxis and sleep disruption) will occur in fewer than 20% of the subjects in this study.
inSleep Technologies, LLC
Industry
Acronym: SNORE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07669870
Apnea, Dyssomnias
Cairo, Egypt
View Trial DetailsNCT07622745
Apnea, Dyssomnias
Cairo, Egypt
View Trial DetailsNCT06900530
Apnea, Dyssomnias
Cleveland, Ohio, United States
View Trial DetailsNCT05371509
Apnea, Dyssomnias
Rochester, Minnesota, United States
View Trial Details